Trial Profile
177Lu-DOTA-octreotate: dosimetry, nephrotoxicity, and the effect of hematological toxicity on survival
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 31 Aug 2018
Price :
$35
*
At a glance
- Drugs Lutetium-(177Lu)-oxodotreotide (Primary)
- Indications Neuroendocrine tumours
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 New trial record